These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28419074)

  • 1. Arymo ER--a new abuse-deterrent morphine formulation.
    Med Lett Drugs Ther; 2017 Apr; 59(1519):68-69. PubMed ID: 28419074
    [No Abstract]   [Full Text] [Related]  

  • 2. Human abuse potential studies of abuse-deterrent opioids: lessons from oral and intranasal studies with morphine abuse-deterrent, extended-release, injection-molded tablets.
    Webster LR; Viscusi ER; Brown C; Dayno JM
    Curr Med Res Opin; 2018 May; 34(5):893-901. PubMed ID: 29368961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphine sulfate abuse-deterrent formulations for the treatment of chronic pain.
    Fanelli A; Sorella MC; Ghisi D
    Expert Rev Clin Pharmacol; 2018 Dec; 11(12):1157-1162. PubMed ID: 30403896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abuse-deterrent features of an extended-release morphine drug product developed using a novel injection-molding technology for oral drug delivery.
    Skak N; Elhauge T; Dayno JM; Lindhardt K
    J Opioid Manag; 2017; 13(6):465-472. PubMed ID: 29308592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ALERRT
    Cone EJ; Buchhalter AR; Lindhardt K; Elhauge T; Dayno JM
    Am J Drug Alcohol Abuse; 2017 May; 43(3):291-298. PubMed ID: 28448223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Drug Liking Study on a Novel Abuse-Deterrent Formulation of Morphine-Morphine ARER.
    Webster LR; Pantaleon C; Shah MS; DiFalco R; Iverson M; Smith MD; Kinzler ER; Aigner S
    Pain Med; 2017 Jul; 18(7):1303-1313. PubMed ID: 27651506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pain and opioids: reasons for an injustice].
    Baños JE
    Med Clin (Barc); 1997 Sep; 109(8):294-6. PubMed ID: 9379751
    [No Abstract]   [Full Text] [Related]  

  • 8. Sustained-release morphine sulfate with sequestered naltrexone for moderate to severe pain: a new opioid analgesic formulation and beyond.
    Ruan X
    Expert Opin Pharmacother; 2011 May; 12(7):999-1001. PubMed ID: 21470064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avinza (morphine sulfate extended-release capsules).
    King CR; Khabazian A
    Clin J Oncol Nurs; 2003; 7(4):458-60, 478. PubMed ID: 12929281
    [No Abstract]   [Full Text] [Related]  

  • 10. The opioid crisis: a 21st century pain.
    Walker G
    Drugs Today (Barc); 2018 Apr; 54(4):283-286. PubMed ID: 29869649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preferential Oxycodone Loss of Physically Manipulated Abuse Deterrent Oxycodone HCl Extended Release Tablets Prepared for Nasal Insufflation Studies.
    Meng Z; Boyce HJ; Sun D; Kinjo M; Raofi S; Li T
    Pharm Res; 2021 Jul; 38(7):1263-1278. PubMed ID: 34128146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abuse-deterrent formulations of opioids: Many questions still to answer.
    Brown RE
    J Opioid Manag; 2017; 13(6):353-356. PubMed ID: 29308581
    [No Abstract]   [Full Text] [Related]  

  • 13. Extended-release epidural morphine (DepoDur).
    Pasero C; McCaffery M
    J Perianesth Nurs; 2005 Oct; 20(5):345-50. PubMed ID: 16246812
    [No Abstract]   [Full Text] [Related]  

  • 14. Do abuse deterrent opioid formulations work?
    Dart RC; Iwanicki JL; Dasgupta N; Cicero TJ; Schnoll SH
    J Opioid Manag; 2017; 13(6):365-378. PubMed ID: 29308584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Legal liability perspectives on abuse-deterrent opioids in the treatment of chronic pain.
    Brushwood DB; Rich BA; Coleman JJ; Bolen J; Wong W
    J Pain Palliat Care Pharmacother; 2010 Dec; 24(4):333-48. PubMed ID: 21133741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new abuse-deterrent opioid--Xtampza ER.
    Med Lett Drugs Ther; 2016 Jun; 58(1497):77-8. PubMed ID: 27305067
    [No Abstract]   [Full Text] [Related]  

  • 17. A morphine/naltrexone combination (Embeda) for pain.
    Med Lett Drugs Ther; 2010 Mar; 52(1334):22-3. PubMed ID: 20336033
    [No Abstract]   [Full Text] [Related]  

  • 18. Syringeability of morphine ARER, a novel, abuse-deterrent, extended-release morphine formulation.
    Kinzler ER; Pantaleon C; Iverson MS; Aigner S
    Am J Drug Alcohol Abuse; 2019; 45(4):377-384. PubMed ID: 30990363
    [No Abstract]   [Full Text] [Related]  

  • 19. Abuse-deterrent opioid formulations.
    Med Lett Drugs Ther; 2015 Aug; 57(1476):119-21. PubMed ID: 26305522
    [No Abstract]   [Full Text] [Related]  

  • 20. Letter to the Editor: Opioid Overdose Protection: An Inevitable Need to Address an Alarming Epidemic.
    Setnik B
    J Opioid Manag; 2017; 13(6):363-364. PubMed ID: 29308583
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.